Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835621 | 1.00 | ACHE (0.42) | ACHEL3MBTL1CTSDTRPM8HTR2A | |
| SCHEMBL851227 | 0.75 | ATM (0.43) | ACHECTSD | |
| SCHEMBL3010604 | 0.73 | SMN1; SMN2 (0.41) | SMN1; SMN2 | |
| SCHEMBL3010600 | 0.73 | SMN1; SMN2 (0.41) | SMN1; SMN2 | |
| SCHEMBL851083 | 0.72 | CARM1 (0.41) | L3MBTL1KMT2AMEN1 | |
| SCHEMBL13197618 | 0.72 | MEN1 (0.44) | L3MBTL1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL13197626 | 0.72 | MEN1 (0.44) | L3MBTL1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL424265 | 0.72 | MEN1 (0.46) | L3MBTL1KMT2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL835699 | 0.71 | ALDH1A1 (0.41) | L3MBTL1KMT2AMEN1 | |
| SCHEMBL532301 | 0.70 | MEN1 (0.47) | L3MBTL1TRPM8KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071194-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | ACHE 1521/4885L3MBTL1 4885/4885CTSD 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.